Cost-Effectiveness of Inotuzumab Ozogamicin Compared to Standard of Care Chemotherapy for Treating Relapsed or Refractory Acute Lymphoblastic Leukaemia Patients in Norway and Sweden.

van Oostrum, I; Russell-Smith, T A; Jakobsson, M; Torup Østby, J; Heeg, B

van Oostrum, I; Russell-Smith, T A; Jakobsson, M; Torup Østby, J; Heeg, B.

Afiliação

van Oostrum I; Ingress-Health, Weena 316-318, 3012 NJ, Rotterdam, The Netherlands.
Russell-Smith TA; Pfizer Inc, New York, USA. Alexander.Smith@pfizer.com.
Jakobsson M; Pfizer Innovations AB, Stockholm, Sweden.
Torup Østby J; Pfizer Inc, Oslo, Norway.
Heeg B; Ingress-Health, Weena 316-318, 3012 NJ, Rotterdam, The Netherlands.

Pharmacoecon Open ; 6(1): 47-62, 2022 Jan.

Article em En | MEDLINE | ID: mdl-34309818

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Health_technology_assessment Idioma: En Revista: Pharmacoecon Open Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google